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Neutrophil unsaturated fatty acid release
by GM-CSF is impaired in cystic fibrosis
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Abstract
Dysregulated inflammation in cystic fibrosis (CF) is attributed to an altered production of inflammatory mediators
derived from polyunsaturated lipids. In comparison to the arachidonic acid (AA) cascade, little is known about the
modulation of docosahexaenoic acid (DHA) membrane release. We compared data on neutrophil DHA- and AA-
release from both control (CT) and patients with CF using [3H]AA or [14C]DHA as a markers for, respectively, AA
and DHA- release. Granulocyte-macrophage-colony stimulating factor stimulated DHA release from CT, but not CF,
neutrophils. Comparison showed that both [14C]DHA and [3H]AA liberated after stimulation was higher in CT than
in CF neutrophils. Since bioactive mediators derived from DHA are resolving factors and those derived from AA are
both pro- and anti- inflammatory, these results suggest that CF is associated with a reduction of the release of
PUFA-precursors of lipooxygenated resolving mediators. This leads to the hypothesis that defects in the resolving
factors production could contribute to the inflammatory dysregulated processes in CF. Furthermore, the methodol-
ogy used may help to improve knowledge on the regulation and resolution of inflammation.
Introduction
Generation of inflammatory mediators is regulated by
cytokines and factors released in the early phase of inflam-
matory and infectious processes. The precursors of bioac-
tive lipid mediators are the polyunsaturated fatty acids
(PUFA) released from membrane phospholipids. Earlier
studies of bioactive lipids introduced the concept that ara-
chidonic acid [20:4, n6; AA] released from membrane
phospholipids by cytosolic phospholipase A2 (cPLA2) is
transformed to several series of potent bioactive eicosa-
noids: prostaglandins, leukotrienes and lipoxins [1]. In
more recent years, novel enzymatic oxygenated products
generated in vivo were identified in pathways initiated
from the precursors eicosapentaenoic acid and docosahex-
aenoic acid (C22:6 n3; DHA). These new families of com-
pounds contribute functionally to the resolution of
inflammation [2-4]. As the discovery of these molecules is
relatively recent and the direct analyses of these com-
pounds requires Liquid Chromatography with Tandem
Mass Spectrometry Detection [3], most of the available
studies have been focused the regulation of AA cascade,
while the modulation of DHA metabolism has been poorly
investigated and, as a consequence, the mechanisms mod-
ulating DHA release are largely unknown.
Knowledge of these mechanisms could be particularly
important for Cystic Fibrosis (CF) patients. CF is the
most common lethal autosomal recessive hereditary dis-
ease in Caucasians and it is due to dysfunction of the
cystic fibrosis transmembrane conductance regulator
gene. The basic defect results in secondary pulmonary
infection and an excessive neutrophil-driven inflamma-
tory response which are responsible for most of the
morbidity and mortality in these patients [5]. The
genetic defect lead also to pancreatic insufficiency, and
CF-related gastrointestinal manifestations [6].
CF is associated with an imbalance in the ratio of essen-
tial PUFA due to a decreased levels of linoleic and docosa-
hexaenoic acid (n3C22:6; DHA) and to a variable excess of
arachidonic acid (n6 C20:4; AA) with respect to DHA [7].
Since in a previous study we showed in CF a lower
neutrophil AA-generation in response to lipopolysac-
charide (LPS) [8], in this study we aimed to investigate
the modulation of DHA release in CF neuttrophils using
a similar approach to that used to elucidate the regula-
tion of AA metabolism, and in particular:
a. to study the release of DHA and AA from neutro-
phils in response to granulocyte-macrophage-colony
stimulating factor (GM-CSF) challenge;
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b. to compare the DHA and AA release between neu-





(40-60 mCi/mmol), and various classes of products were
purchased from Sigma Chemical Company (St. Louis,
MO, USA). Medium and supplementing factors were
obtained from Hyclone Europe Ltd (Sial, Rome, Italy).
Dextran T-70 was obtained from Pharmacia Pfizer Italy.
GM-CSF was purchased from R&D Systems Europe Ltd
(Space Import Export S.r.l, Milan, Italy).
The study was approved by the Ethical Committee of
the University La Sapienza. Written consent was
obtained by patients and controls. 15 CF patients and 18
CT, with an average age of 27 ± 7 and 28 ± 7 years,
respectively, were enrolled in the study. Only non smo-
kers, or subjects that had not smoked for at least 1 year,
were admitted to the study. Diagnosis of CF was con-
firmed by at least two abnormal sweat tests. The CF
genotype and general characteristics of the patients are
reported in Table 1. All patients were in a stable medical
condition, under standard CF therapies such as pancrea-
tic enzyme and vitamin supplementation and did not
have acute infection (negative C-reactive protein). None
of them were taking corticosteroids therapy. None of CT
subjects were on pharmacologic therapies and/or dietary
polyunsaturated fatty acids (PUFA) supplementation.
Neutrophils were isolated from blood samples col-
lected in EDTA according to Boyum [9]. After sedimen-
tation in 3% dextran, the leukocyte-enriched pellet was
layered over a Histopaque 1.077 g/ml and centrifuged at
400 × g for 40 min. Residual erythrocytes were lysed.
The purity of CD16+ neutrophils (phycoerythrin conju-
gated CD16 and isotype-matched Ig from Becton
Dickinson, Milan, Italy) was greater than 90%.
The first step in the generation of biologically impor-
tant eicosanoids in human neutrophils is AA release
from membrane phospholipids by cytosolic phospholi-
pase A2 (cPLA2) [10]. Since AA competes with DHA
for the same enzymes and for the site of esterification at
the sn-2 position of phospholipids, to study [14C]DHA
and [3H]AA-release, we adapted the method reported by
DiPersio et al. [9]. Neutrophils PUFA release was stimu-
lated with GM-CSF at the concentration of 0.2 nM.
These conditions have been shown to be a suitable sti-
mulation for these tests [11]. Neutrophils, at a density of
3×106 cells/ml in RPMI containing 0.3% bovine serum
albumin (BSA), were radiolabelled with [14C]DHA (0.4
μCi/ml) or [3H]-AA (2 μCi/ml) for 3 h at 23°C. After
labelling and washing, the [14C]DHA or [3H]AA release
was tested in RPMI 0.3% BSA in resting (NT) cells or in
cells challenged with 0.2 nM GM-CSF. After 30 min,
duplicate samples of 200 μl centrifuged medium were
assayed for radioactivity by liquid scintillation counting.
Radioactivity associated with neutrophils was counted
after cell lysis with 200 μl of distilled water. Extracellular
[14C]DHA and [3H]AA-release is expressed as a percen-
tage of the total radioactivity incorporated by the cells.
Total radioactivity incorporated into neutrophils takes
account of the activity released into the medium. Each
experimental point was performed in duplicate.
Plasma fatty acid analysis was performed by gas chro-
matography [12]. After lipid extraction and acid catalyzed
Table 1 Cystic fibrosis patient characterisation
Patient Age Sex Genotype BMIa (Kg/m) Diabetes FEV1b (Lt)
1 20 F DF508/852del22 20,4 NO 2,19 (75%)
2 40 M G542X/UN 20,7 NO 0,49 (14%)
3 33 F DF508/1717-1GToA 21,0 YES 2,68 (98%)
4 25 F G542X/N1303K 17,0 YES 0,62 (22%)
5 22 M DF508/L732X 20,0 YES 1,23 (31%)
6 34 M UN/UN 18,0 YES 0,63 (15%)
7 27 F N1303K/N1303K 15,0 YES 0,65 (20%)
8 33 F N1303K/UN 20,0 YES 0,53 (20%)
9 26 F DF508/DF508 19,0 YES 1,04 (35%)
10 36 M G551D/621+1GtoT 21,6 NO 1,61 (37%)
11 21 F DF508/DF508 16,3 NO 1,35 (38%)
12 15 F DF508/UN 18,3 NO 1,05 (38%)
13 27 F DF508/DF508 22,5 NO 1,39 (45%)
14 21 F DF508/DF508 19,4 NO 0,80 (27%)
15 36 M DF508/G542X 21,9 YES 1,35 (46%)
a BMI: Body Mass Index; b Forced Expiratory Volume in 1 Second
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transesterification, plasma fatty acid methyl esters were
analyzed by gas liquid chromatography in a Hewlett-
Packard 5890 Series II gas chromatograph equipped with
a flame ionization response detector, a capillary column
OmegawaxiM 320 (30 m×0.32 mm) and a 0.25 mm film
(Supelco, Inc.). Heptadecanoic acid (C17:0) was used as
internal standard.
Values are expressed in means ± SD. Statistical analysis
and correlation analysis was performed with GraphPad
Instat Ver. 4.03 software. The within group differences
were assessed by a paired sample paradigm by Wilcoxon
matched pairs test. The comparison between the two
independent groups CT and CF data was performed
either by nonparametric one-way ANOVA (Kruskal-
Wallis Test) using Dunn’s Multiple Comparisons test as
post-test or by unpaired t test with Welch correction.
Pearson product moment correlation coefficient was
used to evaluate the correlation between different
variables.
Results
Gas-chromatographic analysis showed that the percentage
of AA (n = 15) and DHA (n = 18) relative to the total fatty
acid content of plasma were, respectively, 7.12 ± 1.39%
and 1.67 ± 0.81% in CF patients and 6.72 ± 2.28% and
1.76 ± 0.79% in the CT group, without differences between
the groups. However, as expected in these patients, the
plasma AA/DHA molar ratio (4.87 ± 2.42 and 3.60 ± 0.81
in CF and CT group, respectively) was significantly higher
in CF (P < 0.05) with respect to CT.
The [14C]DHA release (Table 2) from the membrane
by resting CF neutrophils was not significantly different
than CT cells. However, [14C]DHA release was increased
upon stimulation with GM-CSF in CT neutrophils, but
was scarcely modulated in the CF group. The differences,
in fact, between [14C]DHA release in NT and GM-CSF
conditions were statistically different in the CT group,
but not in the CF group (P < 0.002 and P = 0.09 in CT
and CF, respectively) and consequently, release was sig-
nificantly higher in CT as compared to CF cells after
GM-CSF stimulation (Table 2). In both CF and CT
groups, [14C]DHA release by resting neutrophils was not
correlated with the release upon GM-CSF stimulation, or
with the proportion of DHA or AA in the plasma.
In CT neutrophils, cytokine stimulation induced a
strong increase of the release of [3H]AA (Table 3) with
respect to resting cells (NT vs GM-CSF: P < 0.001), but
CF neutrophils were not responsive to the stimulation
as there was no significant change in [3H]AA release. In
fact, the mean of the [3H]AA released after GM-CSF
challenging from CF neutrophils was markedly lower in
comparison to that from CT cells (GM-CSF: CF vs CT:
P < 0.02).There were no differences in either [14C]DHA
or [3H]AA release between CF patient with (n = 8) and
without (n = 7) diabetes.
There was a positive correlation between the [3H]AA
released in resting conditions and after GM-CSF chal-
lenge, and this was markedly stronger in the CT group
(r = 0.86, p < 0.0005) in comparison to the CF patients
(r = 0.59, p < 0.05). Also, in the control group, but not the
CF group, the neutrophil [3H]AA release positively corre-
lated with the AA plasma content both in resting (r =
0.61, p < 0.02) and stimulated (r = 0.59, p < 0.05)
neutrophils.
Evaluation of the relationship between the radioactive
tests showed that [14C]DHA and the [3H]AA release
were correlated, in resting condition in CF neutrophils
(r = 0.80, p < 0.003), and after the stimulation with
GM-CSF in CT cells (r = 0.77, P < 0.03).
Discussion
AA and the mobilisation of its early metabolites can be
monitored by the release of previously radiolabelled AA
in the membrane pool. This method, described more
than 20 years ago for the measurement of the pro-
inflammatory precursors release by neutrophil
[11,13,14], is still widely used in several fields to test
membrane mobilisation of the mediator precursors
[15-17], but, to the author’s knowledge, it has never
been used to study modulation of the DHA release. In
this work we used [3H]AA or [14C]DHA as a marker
for, respectively, the AA and the DHA-related products
released from the membrane after neutrophil activation.
Table 2 Release of DHA by neutrophils
Neutrophils [14C]DHA release (%)
Mean ± SD (n)
NT GM-CSF
CT 11.1 ± 6.3 (18)a 15.1 ± 6.9 (18)b
CF 9.9 ± 8.1 (15) 8.3 ± 4.4 (15)
a CT: NT vs GM-CSF, p < 0.002
b GM-CSF: CT vs CF, p < 0.05.
The release of [14C]DHA into the medium by neutrophils isolated from control
subjects (CT) and patients with cystic fibrosis (CF) was measured in resting
cells (NT) and after stimulation with GM-CSF (0.2 nM). Data are expressed as a
percentage of the total radioactivity incorporated into the cells.
Table 3 Release of AA by neutrophils
Neutrophils [3H]AA release (%)
Mean ± SD (n)
NT GM-CSF
CT a 6.3 ± 4.8 (16) 10.8 ± 5.7 (16)b
CF 4.1 ± 3.3 (15) 5.4 ± 2.0 (15)
a CT: NT vs GM-CSF, p < 0.01
b GM-CSF: CT vs CF, p < 0.02.
The release of [3H]AA into the medium by neutrophils isolated from control
subjects (CT) and patients with cystic fibrosis (CF) was measured in resting
cells (NT) and after stimulation with GM-CSF (0.2 nM). Data are expressed as a
percentage of the total radioactivity incorporated into the cells.
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GM-CSF was found to elicit a significant enhancement
of [3H]AA released from CT, but not CF neutrophils
(Table 3). In CT neutrophils, the AA cascade triggered
by GM-CSF produced a release of [3H]AA significantly
higher than that observed in resting cells (+71%), and
also than that found in GM-CSF-treated CF neutrophils
(+100%). In contrast, there was no significant increase
in AA-derived precursors released by the CF cells in
response to specific neutrophil stimulation.
In the case of DHA, our results show that regulation
of its liberation from neutrophils is also modulated in
CT subjects differently than in CF patients. Treatment
with GM-CSF induced a significant increase of [14C]
DHA liberated from CT neutrophils (Table 2). Conver-
sely, cells derived from CF patients responded to
GM-CSF challenge with a slight reduction of [14C]DHA
recovered into the medium. As mediators derived from
DHA cascade induce the production of resolvins and
protectins [2-4], families of compounds with resolving
and anti-inflammatory activity, the lack of response to
GM-CSF in CF patients suggests that the liberation of
PUFA precursors of resolving mediators derived from
DHA is markedly impaired in CF neutrophils.
The concept of defective production of mediator pre-
cursors in CF is supported by correlation analysis, as the
releases of the [14C]DHA and the [3H]AA correlate in
CF group in resting condition, whereas in CT group the
same correlation is observed only after stimulation with
GM-CSF, indicating that both the basal response and
the mechanisms regulating precursors liberation are
altered in the CF patients. Furthermore, both in resting
and stimulated CT neutrophils, the [3H]AA released is
correlated with plasma AA content, while this relation-
ship is totally lacking in CF neutrophils, suggesting that
other factors play a greater role than lack/availability of
AA in the regulation of the inflammatory response in
CF neutrophils. In addition, although not definitive, our
results suggest that, in contrast to [3H]AA release, [14C]
DHA release is not correlated with the plasma propor-
tion of either AA or DHA, suggesting that it may be dif-
ficult to regulate resolvins and protectins synthesis by
modifications of availability of DHA in CF as well con-
trol subjects.
In agreement with the data that CF-related diabetes
represents the most common co-morbidity in this dis-
ease [18], about 50% of CF subject were diabetics. Dia-
betes in CF patients depends on the basic genetic defect
and shows important differences with respect to both
type 1 and type 2 diabetes [18]. We found that, although
disturbances in AA cascade are common in type 2 dia-
betes [19], there were no differences in PUFA mem-
brane release in CF-related diabetes.
The dysregulated inflammatory response in CF is com-
monly considered excessive [5], and the abnormalities in
AA release in CF patients have been attributed to an
exaggerated production of proinflammatory mediators
such as leukotrienes and prostaglandins, which exacer-
bated the lung infection in these patients [5,13,14]. How-
ever, in 2004 Karp et al. [20] reported an important
defect in lipoxin and anti-inflammatory activity in CF air-
ways, and suggested that in CF a deficiency of resolving
factors prevents resolution of lung inflammation and
impedes healing. Our results indicate that CF is asso-
ciated with both an impaired regulation by GM-CSF of
the release of PUFA from the membrane and decreased
liberation of DHA and AA precursors, suggesting that
the generation of mediators derived from DHA and AA
in CF is insufficient, rather than excessive. In particular,
as lipooxygenated products derived from DHA have a
major function in infection termination and healing, the
lack of response to GM-CSF may be directly related to
an impaired resolution of infections [21]. Furthermore,
the DHA deficiency associated with CF [7] may worsen
the liberation of appropriate amount of DHA-derived
healing factors.
In conclusion, although future studies are necessary to
clarify the underlying mechanisms of altered PUFA
delivery from CF neutrophils, the preliminary results of
this study indicate a major defect in DHA delivery by
neutrophils delivery in CF and suggests a useful metho-
dological approach for the study of DHA metabolism,
which may help to monitor the early stages of resolving
factor production in response to different therapeutic
interventions.
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